BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27230389)

  • 21. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
    Caobelli F; Chiaravalloti A; Evangelista L; Saladini G; Schillaci O; Vadrucci M; Scalorbi F; Donner D; Alongi P;
    Ann Nucl Med; 2018 Jan; 32(1):7-15. PubMed ID: 28986764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET imaging for thyroid cancers: Current status and future directions.
    Giraudet AL; Taïeb D
    Ann Endocrinol (Paris); 2017 Feb; 78(1):38-42. PubMed ID: 27989550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional nuclear medicine imaging of medullary thyroid cancer.
    Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D
    Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
    Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
    Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study of Medullary Thyroid Carcinoma from a proband].
    Morlán Herrador L; de Arriba A; Miguel G; Ferrera M; Labarta JI
    Arch Argent Pediatr; 2016 Dec; 114(6):e421-e424. PubMed ID: 27869424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
    Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
    J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid incidentaloma identified by ¹⁸F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance.
    Pagano L; Samà MT; Morani F; Prodam F; Rudoni M; Boldorini R; Valente G; Marzullo P; Baldelli R; Appetecchia M; Isidoro C; Aimaretti G
    Clin Endocrinol (Oxf); 2011 Oct; 75(4):528-34. PubMed ID: 21575027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
    Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
    Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
    Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five Patients with Medullary Thyroid Carcinoma Presenting as Asymptomatic Elevation of Carcinoembryonic Antigen Level.
    Tan KT; Tan JZ
    Ann Acad Med Singap; 2015 Jun; 44(6):226-8. PubMed ID: 26292951
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidental thyroid lesions on FDG-PET/CT: a prevalence study and proposition of management.
    Adas M; Adas G; Koc B; Ozulker F
    Minerva Endocrinol; 2015 Sep; 40(3):169-75. PubMed ID: 26205646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.
    Abraham T; Schöder H
    Semin Nucl Med; 2011 Mar; 41(2):121-38. PubMed ID: 21272686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel acquisitions in the diagnosis of medullary thyroid carcinoma.
    Trimboli P; Crescenzi A; Saggiorato E; Treglia G; Giovanella L
    Minerva Endocrinol; 2017 Sep; 42(3):238-247. PubMed ID: 27808486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Raue F; Frank-Raue K
    Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
    Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
    Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.
    Li W; Yin W; Ou R; Chen T; Xiong L; Cheng D; Xie D; Zheng X; Xu Y; Zhao L
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):675-81. PubMed ID: 26497700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.
    Erba PA; Maecke H; Mikolajczak R; Decristoforo C; Zaletel K; Maina-Nock T; Peitl PK; Garnuszek P; Froberg A; Goebel G; de Jong M; Jabrocka-Hybel A; Konijnenberg M; Virgolini I; Nock B; Lenda-Tracz W; Pawlak D; Rangger C; Trofimiuk-Müldner M; Sowa-Staszczak A; Tomaszuk M; von Guggenberg E; Scarpa L; Hubalewska-Dydejczyk A
    Pol Arch Intern Med; 2018 Dec; 128(12):791-795. PubMed ID: 30516761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.